Cipla Ltd
Cipla Ltd (CIPLA) is scheduled to report results on 27 Oct 2026. Cipla Ltd last reported results for the quarter ended Jun 2026, with sales of ₹7,119 crore and net profit of ₹786 crore. The stock last traded at ₹1,301, a market capitalisation of ₹1,05,249 crore, on a P/E of 29.4. Over the past 52 weeks the stock has ranged between ₹1,166 and ₹1,673. Figures are as of 9 Oct 2026 and are not real time.
Cipla Ltd share price and key metrics
- Current price
- ₹1,301
- Market cap
- ₹1,05,249 cr
- Stock P/E
- 29.4
- Book value
- ₹426
- ROE
- 11.6%
- ROCE
- 15.5%
- Dividend yield
- 1.00%
- 52w high / low
- 1673/1166
Metrics as of 9 Oct 2026. Not real time.
Track Cipla Ltd
Cruxal reads every Cipla Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cipla Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 8%
- 3 Years
- 7%
- TTM
- 2%
- 10 Years
- 11%
- 5 Years
- 10%
- 3 Years
- 10%
- TTM
- -34%
- 10 Years
- 8%
- 5 Years
- 7%
- 3 Years
- 4%
- 1 Year
- -14%
- 10 Years
- 13%
- 5 Years
- 14%
- 3 Years
- 15%
- Last Year
- 12%
Cipla Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹7,119 cr, up 2.3% from ₹6,957 cr a year earlier. Net profit was ₹786 cr, down 39.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 |
| Expenses | 5,165 | 5,084 | 5,192 | 5,179 | 5,695 | 5,819 | 5,586 | 5,927 |
| Operating profit | 1,886 | 1,989 | 1,538 | 1,778 | 1,895 | 1,255 | 955 | 1,192 |
| OPM % | 27% | 28% | 23% | 26% | 25% | 18% | 15% | 17% |
| Other income | 191 | 222 | 289 | 259 | 269 | -70 | 148 | 211 |
| Interest | 15 | 15 | 14 | 14 | 13 | 14 | 13 | 17 |
| Depreciation | 272 | 280 | 309 | 253 | 297 | 278 | 383 | 304 |
| Profit before tax | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,082 |
| Tax % | 27% | 17% | 19% | 27% | 27% | 24% | 22% | 27% |
| Net profit | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 |
| EPS (₹) | 16.13 | 19.45 | 15.13 | 16.06 | 16.73 | 8.37 | 6.87 | 9.77 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Cipla Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14,394 | 15,156 | 16,362 | 17,132 | 19,160 | 21,763 | 22,753 | 25,774 | 27,548 | 28,163 | 28,324 |
| Operating profit | 2,496 | 2,826 | 3,097 | 3,206 | 4,252 | 4,553 | 5,027 | 6,291 | 7,128 | 5,883 | 5,297 |
| OPM % | 17% | 19% | 19% | 19% | 22% | 21% | 22% | 24% | 26% | 21% | 19% |
| Net profit | 1,035 | 1,417 | 1,492 | 1,500 | 2,389 | 2,547 | 2,833 | 4,154 | 5,269 | 3,862 | 3,356 |
| EPS (₹) | 12.51 | 17.52 | 18.96 | 19.18 | 29.82 | 31.19 | 34.71 | 51.05 | 65.28 | 48.02 | 41.74 |
TTM is the trailing twelve months to the most recent quarter.
Cipla Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 | 162 |
| Reserves | 12,383 | 14,068 | 14,851 | 15,602 | 18,165 | 20,680 | 23,246 | 26,545 | 31,032 | 34,270 |
| Borrowings | 4,113 | 4,098 | 4,316 | 2,816 | 2,014 | 1,056 | 803 | 559 | 438 | 614 |
| Other liabilities | 4,213 | 4,346 | 4,433 | 4,843 | 4,514 | 4,960 | 5,089 | 5,267 | 5,702 | 7,297 |
| Total liabilities | 20,869 | 22,673 | 23,762 | 23,423 | 24,855 | 26,857 | 29,300 | 32,533 | 37,334 | 42,343 |
| Fixed assets | 9,492 | 9,950 | 9,608 | 9,683 | 9,516 | 9,683 | 9,160 | 9,607 | 10,006 | 12,434 |
| CWIP | 1,683 | 981 | 676 | 825 | 969 | 766 | 1,093 | 1,153 | 1,566 | 2,042 |
| Investments | 973 | 1,259 | 2,554 | 1,471 | 2,710 | 2,551 | 3,662 | 5,449 | 7,933 | 8,223 |
| Other assets | 8,721 | 10,483 | 10,923 | 11,444 | 11,661 | 13,857 | 15,384 | 16,323 | 17,828 | 19,643 |
| Total assets | 20,869 | 22,673 | 23,762 | 23,423 | 24,855 | 26,857 | 29,300 | 32,533 | 37,334 | 42,343 |
As reported by the company. Total assets equal total liabilities by construction.
Cipla Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | 3,238 | 4,134 | 5,005 | 3,940 |
| Cash from investing | -1,304 | -834 | -1,688 | 114 | -2,374 | -1,858 | -2,376 | -2,982 | -3,682 | -2,234 |
| Cash from financing | -1,326 | -385 | -349 | -2,949 | -1,240 | -1,600 | -958 | -1,200 | -1,293 | -1,234 |
| Net cash flow | -248 | 243 | -345 | 234 | 141 | -132 | -97 | -49 | 30 | 473 |
| Free cash flow | 1,284 | 723 | 1,187 | 2,083 | 2,964 | 2,645 | 2,102 | 2,819 | 3,490 | 928 |
| CFO / operating profit | 113% | 77% | 74% | 122% | 113% | 98% | 90% | 91% | 94% | 94% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Cipla Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 7% | 9% | 11% | 12% | 17% | 17% | 18% | 23% | 23% | 15% |
| Debtor days | 65 | 75 | 93 | 83 | 66 | 57 | 65 | 68 | 73 | 73 |
| Inventory days | 239 | 271 | 250 | 267 | 232 | 230 | 228 | 217 | 231 | 252 |
| Days payable | 108 | 142 | 123 | 139 | 103 | 108 | 112 | 102 | 116 | 123 |
| Cash conversion cycle | 196 | 204 | 220 | 211 | 195 | 180 | 181 | 182 | 188 | 202 |
| Working capital days | 99 | 118 | 132 | 113 | 94 | 95 | 113 | 120 | 128 | 106 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Cipla Ltd shareholding pattern
Promoters held 29.22% at Jun 2026, broadly unchanged since Jun 2025. FIIs 20.20% and DIIs 34.35%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 30.93% | 29.19% | 29.20% | 29.19% | 29.22% | 29.22% | 29.22% | 29.22% |
| FIIs | 28.80% | 26.65% | 26.28% | 25.24% | 24.54% | 23.93% | 22.55% | 20.20% |
| DIIs | 23.95% | 27.49% | 27.89% | 28.98% | 29.98% | 30.45% | 31.71% | 34.35% |
| Government | 0.21% | 0.23% | 0.26% | 0.27% | 0.27% | 0.27% | 0.27% | 0.28% |
| Public | 16.11% | 16.43% | 16.36% | 16.30% | 15.99% | 16.12% | 16.26% | 15.93% |
| No. of shareholders | 4,70,234 | 5,25,114 | 5,43,420 | 5,49,655 | 5,34,587 | 5,40,521 | 5,84,217 | 5,78,679 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Cipla Ltd’s next results date?
Cipla Ltd’s next results are scheduled for 27 Oct 2026.
- Earnings resultsConsider and approve unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Cipla Ltd corporate filings
- Cipla Limited schedules Board Meeting for 27th October 2026 to approve Q2 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Cipla Limited has formally intimated the stock exchanges regarding a Board of Directors…
Read the full analysis - Cipla Ltd allots 12,168 equity shares under ESOP and ESAR schemesCompany Updatelow impact
Cruxal's analysis: Cipla Ltd has allotted 12,168 fully paid-up equity shares of face value INR 2 each on…
Read the full analysis - Cipla announces internal leadership transition for Global Head of Supply ChainCompany Updatelow impact
Cruxal's analysis: Cipla Limited has announced that Mr. Venkata Sai Mungara, currently the Global Head of…
Read the full analysis - Cipla Ltd discloses ESG rating updateCompany Updatelow impact
Cruxal's analysis: Cipla Ltd has submitted a disclosure regarding its ESG rating in compliance with…
Read the full analysis - Cipla enters exclusive partnership with Qilu Pharmaceutical for US biosimilar licensing of PembrolizumabCompany Updatemedium impact
Cruxal's analysis: Cipla has signed an exclusive licensing and supply agreement with Qilu Pharmaceutical to…
Read the full analysis - Cipla Limited initiates NCLT-mandated notice process for the amalgamation of Inzpera Healthsciences LimitedCompany Updatelow impact
Cruxal's analysis: Cipla Limited has commenced the regulatory process to notify shareholders and unsecured…
Read the full analysis - Cipla Ltd announces special window for re-lodgement and dematerialisation of physical sharesCompany Updatelow impact
Cruxal's analysis: Cipla Ltd has published a newspaper notice regarding the opening of a special window for…
Read the full analysis - Cipla signs exclusive licensing agreement with SBP Group for HER2 bispecific ADC Rolditamig DeuderuxtecanCompany Updatemedium impact
Cruxal's analysis: Cipla has entered into an exclusive licensing agreement with SBP Group to develop and…
Read the full analysis - Cipla Ltd provides update on USFDA inspection at Invagen manufacturing facilityCompany Updatelow impact
Cruxal's analysis: Cipla Ltd has issued a disclosure regarding a USFDA inspection at its Invagen…
Read the full analysis - Cipla Ltd files disclosure regarding corporate restructuring under Regulation 30Company Updatelow impact
Cruxal's analysis: Cipla Ltd has submitted a disclosure under Regulation 30 of the SEBI (LODR) Regulations…
Read the full analysis - Cipla Ltd schedules analyst and institutional investor meetingsCompany Updatelow impact
Cruxal's analysis: Cipla Ltd has issued a routine intimation regarding a scheduled meeting with analysts and…
Read the full analysis - Cipla Ltd allots 5,281 equity shares under ESOP and SAR schemesCompany Updatelow impact
Cruxal's analysis: Cipla Ltd has allotted 5,281 fully paid-up equity shares of face value INR 2 each on…
Read the full analysis - Cipla Ltd discloses USFDA inspection at Pithampur manufacturing facilityCompany Updatelow impact
Cruxal's analysis: Cipla Ltd has formally disclosed that the US Food and Drug Administration (USFDA) is…
Read the full analysis - Cipla receives NCLT approval for the amalgamation of wholly-owned subsidiary Inzpera Healthsciences LimitedCompany Updatelow impact
Cruxal's analysis: Cipla Limited has received approval from the National Company Law Tribunal (NCLT) for the…
Read the full analysis - Cipla Ltd discloses ESG ratings in compliance with SEBI Regulation 30Company Updatelow impact
Cruxal's analysis: Cipla Ltd has submitted a disclosure regarding its ESG ratings as part of its routine…
Read the full analysis - Cipla provides generic update on USFDA inspection at Invagen's Hauppauge, New York facilityCompany Updatelow impact
Cruxal's analysis: Cipla Ltd. has issued an intimation regarding the USFDA inspection at its Invagen…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.